



Australian Government

Department of Health, Disability and Ageing
Therapeutic Goods Administration

Mr Geoff Acton
Managing Director
Antaria Pty Ltd
Unit 1 & 2 /81 Shettleston Street
ROCKLEA QLD 4106

TGA Reference: E19-534096

Subject: Reissue of licence to manufacture therapeutic goods MI-2019-LI-02603-1

Dear Mr Acton,

Please find enclosed the reissued Licence Part 1 (Authorisations) and Part 2 (Schedule of Conditions) for your manufacturing premises as requested.

Please do not hesitate to contact the Manufacturing Quality Branch if you require any further information.

Yours sincerely,

Signed and authorised by

Maurice Makdessi
Delegate of the Secretary
Manufacturing Quality Branch

17 February 2026

Contact: GMP@health.gov.au, Phone: 1800 020 653



Australian Government

Department of Health, Disability and Ageing
Therapeutic Goods Administration

Licence to Manufacture Therapeutic Goods – Part 1

Licence Number:

MI-2019-LI-02603-1

Granted to:

Antaria Pty Ltd
ABN: 36 092 404 727

Manufacturing Site Address:

Unit 1 & 2 /81 Shettleston Street
ROCKLEA QLD 4106

The manufacturer above is hereby authorised under Section 38 of the *Therapeutic Goods Act 1989* to carry out the following steps in the manufacture of therapeutic goods at the manufacturing site address specified above.

Manufacturing Type	Sterility	Dosage Form	Product Category	Manufacturing Step
Active Pharmaceutical Ingredient manufacture	Non Sterile	API - Not Defined	Not Applicable	Active material manufacture
Sunscreen manufacture	Non Sterile	Topical Sunscreen Forms, Liquids Group	Listed Therapeutic Good	Manufacture of dosage form
Sunscreen manufacture	Non Sterile	Topical Sunscreen Forms, Semi Solids	Listed Therapeutic Good	Manufacture of dosage form

This licence is subject to the requirements of the *Therapeutic Goods Act 1989*, and its Regulations.

Section 40(4) of the *Therapeutic Goods Act 1989* and Regulation 19, 20, 21 and 22 of the Therapeutic Goods Regulations 1990 impose various statutory conditions on all licences to manufacture therapeutic goods.

In addition to that, the specific conditions mentioned in Part 2 of this licence have been imposed under Section 40(1) or 40(2) of the *Therapeutic Goods Act 1989*.

Originally Granted: 17 September 2019

Date Revised: 17 February 2026

This licence is the property of the Therapeutic Goods Administration and must be returned or destroyed upon demand.
This licence remains valid until otherwise suspended or revoked by the Therapeutic Goods Administration.
The status of an Australian licence may be viewed at <https://www.ebs.tga.gov.au/>



Australian Government

Department of Health, Disability and Ageing
Therapeutic Goods Administration

Licence to Manufacture Therapeutic Goods – Part 2: Schedule of Conditions

Licence Number:

MI-2019-LI-02603-1

Granted to:

Antaria Pty Ltd
ABN: 36 092 404 727

Manufacturing Site Address:

Unit 1 & 2 /81 Shettleston Street
ROCKLEA QLD 4106

In addition to the statutory conditions that have been imposed on all licences to manufacture therapeutic goods under Section 40(4) of the *Therapeutic Goods Act 1989* and Regulations 19, 20 and 21 of the Therapeutic Goods Regulations 1990, the conditions specified below have been imposed on this licence under Section/s 40(1) and/or 40(2) of the *Therapeutic Goods Act 1989*:

The manufacture of non-sterile APIs is limited to non-sterile APIs and Proprietary Ingredient containing zinc oxide.

This licence does not authorise the chemical/physical testing and microbial testing for the APIs and Proprietary Ingredient containing zinc oxide, and non-sterile listed topical sunscreen products.

This licence does not authorise the release for supply for the APIs and Proprietary Ingredient containing zinc oxide, and non-sterile listed topical sunscreen products.

This licence does not authorise the manufacture of medicines listed for export that include substances at a level only permitted in medicines contained within schedules 2, 3, 4 & 8 of the Poisons Standard.

Persons currently nominated under Section 37(1)(e) of the Act as having control:

Production: Patrick A Baxter

Quality Control: Kelly O'Rourke

Originally Granted: 17 September 2019

Date Revised: 16 February 2026

This licence is the property of the Therapeutic Goods Administration and must be returned or destroyed upon demand.
This licence remains valid until otherwise suspended or revoked by the Therapeutic Goods Administration.
The status of an Australian licence may be viewed at <https://www.ebs.tga.gov.au/>